Cancer Research on Prevention and Treatment    2022, Vol. 49 Issue (08) : 747-755     DOI: 10.3971/j.issn.1000-8578.2022.22.0377
|
Theoretical Update of Cancer Evo-Dev and Its Role in Targeted Immunotherapy for Hepatocellular Carcinoma
CAO Guangwen
Department of Epidemiology, Faculty of Naval Medicine, Second Military Medical University, Shanghai 200433, China
Download: PDF(4045 KB)   ( 81 )   HTML ()
Export: BibTeX | EndNote | Reference Manager | ProCite | RefWorks
Abstract Abstract: Primary liver cancer (PLC) is the first leading cause of immature cancer death in China. Hepatocellular carcinoma (HCC) in China accounts for 93.0% of PLC. Chronic infection with hepatitis B virus (HBV) HCC contributes to 84.4% of HCC. During HBV-induced hepatocarcinogenesis, non-resolving inflammation facilitates viral and host genome mutations via the up-regulated expression of activationinduced cytidine deaminase/APOBEC3s and decreases mutation repair via the down-regulated expression of uracil DNA glycosylase by proinflammatory cytokines such as interleukin-6. The proinflammatory tumor microenvironment (TME) provides necessary conditions for the “mutation-selection-adaptation” evolutionary process of HBV and human hepatocytes and facilitates the retrodifferentiation of mutated hepatic cells. This evolutionary process has two prerequisites: driving somatic mutations and immune-suppressive TME. Cancerpromoting chromosome instability and viral mutations inhibit type I interferon signaling via activating the cyclic GMP-AMP synthase stimulator of interferon genes, induce immune-suppressive inflammation, and recruit immune-suppressive immune cells, including tumor-associated macrophages, regulatory T cells, and myeloid-derived suppressor cells, to build immunosuppressive TME. In the TME, the rapid growth of tumor cell-caused hypoxia activates kynurenine metabolism in the HCC tissues by inducing the expression of immune-suppressive inflammatory factors to promote the expression of PD-1 on regulatory T cells forenhanced immunosuppression; it also inhibits the cytotoxicities of CD8+T and natural killer cells and facilitates angiogenesis. The theoretical update of “Cancer Evo-Dev” highlights the direction of cancer prophylaxis and treatment. The treatments targeting angiogenesis significantly inhibit the growth of HCC, increase anti-tumoral immunity, and enhance the efficacy of immunotherapy. The combination of targeted therapy and immunotherapy should be the major therapeutic option for the treatment of advanced liver cancer.
Keywords Hepatitis B virus      Hepatocellular carcinoma      Tumor microenvironment      Mutation      Targeted therapy      Immunotherapy     
ZTFLH:  R735.7  
Fund:National Key Basic Research Program of China (973 Program) (No. 2015CB554000); National Natural Science Foundation of China (No. 81673250); Key Discipline from the “3-year Public Health Promotion” Program of Shanghai Municipal Health Commission (No. GWV-10.1-XK17)
Issue Date: 11 August 2022
 Cite this article:   
CAO Guangwen. Theoretical Update of Cancer Evo-Dev and Its Role in Targeted Immunotherapy for Hepatocellular Carcinoma[J]. Cancer Research on Prevention and Treatment, 2022, 49(08): 747-755.
 URL:  
http://www.zlfzyj.com/EN/10.3971/j.issn.1000-8578.2022.22.0377
http://www.zlfzyj.com/EN/Y2022/V49/I08/747
Service
E-mail this article
E-mail Alert
RSS
Articles by authors
CAO Guangwen
[1] Jiang D, Zhang L, Liu W, et al. Trends in cancer mortality in China
from 2004 to 2018: A nationwide longitudinal study[J]. Cancer
Commun (Lond), 2021, 41(10): 1024-1036.
[2] Bray F, Laversanne M, Weiderpass E, et al. The ever-increasing
importance of cancer as a leading cause of premature death
worldwide[J]. Cancer, 2021, 127(16): 3029-3030.
[3] Lin J, Zhang H, Yu H, et al. Epidemiological Characteristics of
Primary Liver Cancer in Mainland China From 2003 to 2020:
A Representative Multicenter Study[J]. Front Oncol, 2022, 12:
906778.
[4] 陶常诚, 张凯, 荣维淇, 等. 肝细胞癌根治术后早期复发及其
时间点的研究进展[J]. 肿瘤防治研究, 2022, 49(4): 359-363.
[Tao CC, Zhang K, Rong WQ, et al. Research Progress of Early
Recurrence and Cut-off Time of Hepatocellular Carcinoma after
Radical Hepatectomy[J]. Zhong Liu Fang Zhi Yan Jiu, 2022,
49(4): 359-363.]
[5] Hu H, Qi S, Zeng S, et al. Importance of Microvascular
Invasion Risk and Tumor Size on Recurrence and Survival of
Hepatocellular Carcinoma After Anatomical Resection and Nonanatomical
Resection[J]. Front Oncol, 2021, 11: 621622.
[6] Yin J, Chen X, Li N, et al. Compartmentalized evolution of
hepatitis B virus contributes differently to the prognosis of
hepatocellular carcinoma[J]. Carcinogenesis, 2021, 42(3):
461-470.
[7] Yin J, Li N, Han Y, et al. Effect of antiviral treatment with nucleotide/nucleoside analogs on postoperative prognosis
of hepatitis B virus-related hepatocellular carcinoma: a twostage
longitudinal clinical study[J]. J Clin Oncol, 2013, 31(29):
3647-3655.
[8] Wang S, Shi H, Liu T, et al. Mutation profile and its correlation
with clinicopathology in Chinese hepatocellular carcinoma
patients[J]. Hepatobiliary Surg Nutr, 2021, 10(2): 172-179.
[9] Chaudhary K, Poirion OB, Lu L, et al. Multimodal Meta-Analysis
of 1,494 Hepatocellular Carcinoma Samples Reveals Significant
Impact of Consensus Driver Genes on Phenotypes[J]. Clin Cancer
Res, 2019, 25(2): 463-472.
[10] Zhang S, Zhou YF, Cao J, et al. mTORC1 Promotes ARID1A
Degradation and Oncogenic Chromatin Remodeling in
Hepatocellular Carcinoma[J]. Cancer Res, 2021, 81(22):
5652-5665.
[11] Péneau C, Imbeaud S, La Bella T, et al. Hepatitis B virus
integrations promote local and distant oncogenic driver alterations
in hepatocellular carcinoma[J]. Gut, 2022, 71(3): 616-626.
[12] An J, Kim D, Oh B, et al. Comprehensive characterization of viral
integrations and genomic aberrations in HBV-infected intrahepatic
cholangiocarcinomas[J]. Hepatology, 2022, 75(4): 997-1011.
[13] 孙秋月, 孙力超, 张稚淳, 等. 基于CiteSpace的肿瘤干细胞研
究态势的文献计量学分析[J]. 肿瘤防治研究, 2021, 48(9):
839-845. [Sun QY, Sun LC, Zhang ZC, et al. Trends in Research
of Cancer Stem Cells: A Bibliometric Analysis Based on
CiteSpace[J]. Zhong Liu Fang Zhi Yan Jiu, 2021, 48(9): 839-845.]
[14] Sangro B, Sarobe P, Hervás-Stubbs S, et al. Advances in
immunotherapy for hepatocellular carcinoma[J]. Nat Rev
Gastroenterol Hepatol, 2021, 18(8): 525-543.
[15] Wu S, Turner KM, Nguyen N, et al. Circular ecDNA promotes
accessible chromatin and high oncogene expr‍ession[J]. Nature,
2019, 575(7784): 699-703.
[16] Hsu CW, Chu YD, Lai MW, et al. Hepatitis B Virus Covalently
Closed Circular DNA Predicts Postoperative Liver Cancer
Metastasis Independent of Virological Suppression[J]. Cancers
(Basel), 2021, 13(3): 538.
[17] Bakhoum SF, Cantley LC. The Multifaceted Role of Chromosomal
Instability in Cancer and Its Microenvironment[J]. Cell, 2018,
174(6): 1347-1360.
[18] Hanahan D. Hallmarks of Cancer: New Dimensions[J]. Cancer
Discov, 2022, 12(1): 31-46.
[19] Liu W, Deng Y, Li Z, et al. Cancer Evo-Dev: A Theory of
Inflammation-Induced Oncogenesis[J]. Front Immunol, 2021, 12:
768098.
[20] Chen L, Zhang Q, Chang W, et al. Viral and host inflammationrelated
factors that can predict the prognosis of hepatocellular
carcinoma[J]. Eur J Cancer, 2012, 48(13): 1977-1987.
[21] Zheng X, Wang P, Li L, et al. Cancer-Associated Fibroblasts
Promote Vascular Invasion of Hepatocellular Carcinoma via
Downregulating Decorin-integrin β1 Signaling [J]. Front Cell Dev
Biol, 2021, 9: 678670.
[22] Song M, He J, Pan QZ, et al. Cancer-Associated Fibroblast-
Mediated Cellular Crosstalk Supports Hepatocellular Carcinoma
Progression[J]. Hepatology, 2021, 73(5): 1717-1735.
[23] Zhang Q, He Y, Luo N, et al. Landscape and Dynamics of Single
Immune Cells in Hepatocellular Carcinoma[J]. Cell, 2019, 179:
829-845.
[24] Lin CA, Chang LL, Zhu H, et al. Hypoxic microenvironment and
hepatocellular carcinoma treatment[J]. Hepatoma Res, 2018, (6):
104-111.
[25] Kumagai S, Koyama S, Itahashi K, et al. Lactic acid promotes
PD-1 expr‍ession in regulatory T cells in highly glycolytic tumor
microenvironments [J]. Cancer Cell, 2022, 40(2): 201-218.
[26] Watson MJ, Vignali PDA, Mullett SJ, et al. Metabolic support of
tumour-infiltrating regulatory T cells by lactic acid[J]. Nature,
2021, 591: 645-651.
[27] Wu S, Xing X, Wang Y, et al. The pathological significance of
LOXL2 in pre-metastatic niche formation of HCC and its related
molecular mechanism[J]. Eur J Cancer, 2021, 147: 63-73.
[28] Krishnan MS, Rajan Kd A, Park J, et al. Genomic Analysis
of Vascular Invasion in HCC Reveals Molecular Drivers and
Predictive Biomarkers[J]. Hepatology, 2021, 73(6): 2342-2360.
[29] Krishnamurthy S, Gilot D, Ahn SB, et al. Involvement of
Kynurenine Pathway in Hepatocellular Carcinoma[J]. Cancers
(Basel), 2021, 13(20): 5180.
[30] Liu W, Wu J, Yang F, et al. Genetic Polymorphisms Predisposing
the Interleukin 6-Induced APOBEC3B-UNG Imbalance Increase
HCC Risk via Promoting the Generation of APOBEC-Signature
HBV Mutations[J]. Clin Cancer Res, 2019, 25(18): 5525-5536.
[31] Liu W, Ji H, Zhao J, et al. Transcriptional repression and apoptosis
influence the effect of APOBEC3A/3B functional polymorphisms
on biliary tract cancer risk[J]. Int J Cancer, 2022, 150(11):
1825-1837.
[32] Tan X, Zheng S, Liu W, et al. Effect of APOBEC3A functional
polymorphism on renal cell carcinoma is influenced by tumor
necrosis factor-α and transcriptional repressor ETS1[J]. Am J
Cancer Res, 2021, 11(9): 4347-4363.
[33] Chen X, Zhang M, Li N, et al. Nucleotide variants in hepatitis
B virus preS region predict the recurrence of hepatocellular
carcinoma[J]. Aging (Albany NY), 2021, 13(18): 22256-22275.
[34] Pu R, Liu W, Zhou X, et al. The Effects and Underlying
Mechanisms of Hepatitis B Virus X Gene Mutants on the
Development of Hepatocellular Carcinoma[J]. Front Oncol, 2022,
12: 836517.
[35]Chen S, Morine Y, Tokuda K, et al. Cancer?associated
fibroblast?induced M2?polarized macrophages promote
hepatocellular carcinoma progression via the plasminogen
activator inhibitor?1 pathway[J]. Int J Oncol, 2021, 59(2): 59.
[36] 丁一波, 陈一凡, 曹广文. 癌症进化发育学的新证据:结直
肠癌和肝细胞癌的研究发现[J]. 中国癌症防治杂志, 2020,
12(1): 1-5. [Ding YB, Chen YF, Cao GW. Novel Evidence of
Cancer Rev-Dev: the Discovery in Colorectal Carcinoma and
Hepatocellular Carcinoma[J]. Zhongguo Ai Zeng Fang Zhi Za
Zhi, 2020, 12(1): 1-5.]
[37] Wang SZ, Lee SD, Sarkar D, et al. Immunological characterization
of hepatocellular carcinoma[J]. Hepatoma Res, 2021, 7(1): 65-88.
[38] Feng ZY, Xu FG, Liu Y, et al. The immune microenvironment
and progression of immunotherapy and combination therapeutic
strategies for hepatocellular carcinoma[J]. Hepatoma Res, 2021,
7(1): 23-37.
[39] Jin H, Shi Y, Lv Y, et al. EGFR activation limits the response of
liver cancer to lenvatinib[J]. Nature, 2021, 595(7869): 730-734.
Related articles from Frontiers Journals
[1] WU Zhuochao, HUANG Zhaohui, . Advances in Tumor-associated Macrophages in Cancer Radiotherapy[J]. Cancer Research on Prevention and Treatment, 2022, 49(09): 870-874.
[2] YANG Junyuan, CAI Hongbing. Countermeasures and Mechanisms of Drug Resistance in Immunotherapy for Cervical Cancer[J]. Cancer Research on Prevention and Treatment, 2022, 49(09): 886-892.
[3] YIN Zhucheng, LIANG Xinjun. Research Progress on Combined Immunotherapy for Microsatellite Stable Colorectal Cancer#br#[J]. Cancer Research on Prevention and Treatment, 2022, 49(09): 977-981.
[4] KANG Yikun, YUAN Peng. Advances in Treatment of Triple Negative Breast Cancer[J]. Cancer Research on Prevention and Treatment, 2022, 49(08): 812-819.
[5] YIN Zhucheng, LIANG Xinjun. Research Progress on Hyperthermia and Anti-Tumor Immunity[J]. Cancer Research on Prevention and Treatment, 2022, 49(08): 827-831.
[6] XIA Siyu, ZHAO Zitong, LI Li. Correlation Between STK11 Gene Mutation and Immunotherapy of Non-small Cell Lung Cancer[J]. Cancer Research on Prevention and Treatment, 2022, 49(08): 850-854.
[7] CHEN Yarui, WANG Jiangtao, GUAN Quanlin, JI Wei, JIAO Fuzhi. Research Progress of Antibody-drug Conjugates in Advanced Non-small Cell Lung Cancer[J]. Cancer Research on Prevention and Treatment, 2022, 49(08): 855-860.
[8] CHEN Weichang, SHI Tongguo, ZHU Jinghan, SUN Linqing, LI Juntao. Progress on Immunotherapy of Gastrointestinal Cancer[J]. Cancer Research on Prevention and Treatment, 2022, 49(07): 639-643.
[9] ZHOU Zhipeng, YANG Mingzhu, CAI Mingqin, XUE Juandi, LYU Xiaoyun. Mechanism of Astragaloside IV on HepG2 Cells Based on Molecular Dynamics Simulation and Experimental Evaluation[J]. Cancer Research on Prevention and Treatment, 2022, 49(07): 655-661.
[10] ZHOU Silei, SUN Guanqun, ZENG Tanlun, CHENG Zhuo, LIANG Xijun. Expression and Prognostic Value of CK2α' in Hepatocellular Carcinoma[J]. Cancer Research on Prevention and Treatment, 2022, 49(07): 662-666.
[11] JIN Tongtong, ZHOU Chuan, WANG Chao, DA Zijian, ZHOU Fenghai, . Research Hotspots and Frontiers of Immunotherapy for Prostate Cancer: A Visual Analysis[J]. Cancer Research on Prevention and Treatment, 2022, 49(07): 667-674.
[12] WU Wei, JING Doudou, CAO Li, PU Feifei, SHAO Zengwu. Current Status and Prospects of Immunotherapy for Osteosarcoma[J]. Cancer Research on Prevention and Treatment, 2022, 49(07): 721-726.
[13] CHEN Bojin, HU Xingyi, ZHAO Jingwen, ZHENG Aihong. Current Status of Immunotherapy in Neoadjuvant Therapy for Gastric Cancer[J]. Cancer Research on Prevention and Treatment, 2022, 49(07): 727-732.
[14] WAN Xiaoying, ZHOU Songwen. Research Progress of M2-type Tumor-associated Macrophages in Lung Cancer[J]. Cancer Research on Prevention and Treatment, 2022, 49(07): 733-737.
[15] ZHANG Jianning, LIU Congwei. Progress of Novel Treatment Options for Glioma[J]. Cancer Research on Prevention and Treatment, 2022, 49(06): 505-513.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed